Despite factors that include a current population of people who are obese and do not exercise or eat as healthy as recommended, Michael Weber, MD, explains that the epidemiology of cardiometabolic conditions has improved due to the developments of more tolerable, effective pharmaceutical agents.
Dr Weber continues by discussing how there has been a decline in cardiovascular events thanks to these agents, which most notably have improved the outlook on hypertension and lipid disorders.
However, when assessing which cardiometabolic conditions have improved the most, Dr Weber concludes that diabetes is lagging behind and determines that more effective treatments for diabetes are necessary.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Impact of Hospital-Physician Integration on Medicare Patient Mix
April 11th 2025This study found no evidence that hospital employment of physicians resulted in physicians treating sicker patients, undercutting claims that hospital-employed physicians serve a higher-acuity patient mix.
Read More